Periodic Reporting for period 2 - INTEGRATE (Personalised Medicine for Intervertebral Disc Regeneration- Integrating Profiling, Predictive Modelling and Gene Activated Biomaterials)
Reporting period: 2022-03-01 to 2023-08-31
AIM1: The first aim involves microenvironmental profiling, predictive screening, and in silico modeling. The work performed under this aim involves (1) obtaining human nucleus pulposus (NP) and annulus fibrosus tissue from patients undergoing discectomy procedures and animal tissues and (2) to determine the microenvironmental profile with respect to pH, glucose, oxygen, osmolarity, and cytokine presence within the tissue. A high throughput micro-spheroid culture system was developed to determine metabolic consumption rates and matrix synthesis rates of both NP and annulus fibrosus cells in a 3D configuration. In silico models were developed to predict the effect of cell injection on the disc microenvironment and matrix regeneration capacity. The results showed that regeneration is feasible in the rat within a 12-week timeframe and in the goat within a 12-month timeframe. Further, it predicts deterioration of a mildly degenerated Grade III disc over ten years without curative cell injection, while five million cells are necessary to prevent GAG content from diminishing further in the substantially larger human IVD.
AIM2: The second aim involves developing injectable gene-activated biomaterials to modulate regeneration and inflammation. Work performed under this aim involved screening several vectors for miRNA delivery and identifying suitable miRNA-activated cell types. A homing effect was observed when using the FLR-mediated nanoparticle delivery, which provides a promising approach for therapies of the intradiscal space. Work has also commenced to develop injectable miRNA-activated stem cell microcapsules and extracellular matrix hydrogels to modulate matrix synthesis and inflammation.
AIM: The third aim focuses on pre-clinical evaluation in a large animal model. The team have conducted substantial work in order to prepare for the large animal study, including characterising the lumbar discs of goats. This information is important in designing the animal study, as it will guide decisions regarding the assignment of lumbar levels, injectable treatment volumes, and cell doses relative to the native cell population. An ethics application for the large animal work is currently underway.
• In silico modelling of intradiscal cell delivery and matrix synthesis to predict regeneration: We have demonstrated using our first-generation diffusion reaction models the first-ever in silico models to simulate intradiscal cell delivery and matrix synthesis, which can predict regeneration effects in both animal and human discs. Our findings correlate favourably to the pre-clinical literature in terms of the capabilities of animal regeneration and predict that compromised nutrition is not a significant challenge in small animal discs. On the contrary, it highlights a very fine clinical balance between an adequate cell dose for sufficient repair, through de novo matrix deposition, without exacerbating the human microenvironmental niche. Our current work is focused on refining these models by profiling of microenvironmental factors from extracted human and animal disc tissue to determine how specific factors alter metabolism and matrix synthesis. By the end of this award, it is anticipated that we will have the first complete measurements of intradiscal microenvironmental factors in human discs. Ultimately, this work provides a platform to inform the design of clinical trials, and as computing power and software capabilities increase, it is conceivable that the future holds the generation of patient-specific models which could be used for patient assessment, as well as pre- and intraoperative planning.